Evidence map›Paper›PMID 39708910›Full record

ArticleMolecular & cellular proteomics : MCP2025

Development of a High-Throughput Platform for Quantitation of Histone Modifications on a New QTOF Instrument.

Emily Zahn, Yixuan Xie, Xingyu Liu, Rashmi Karki, Richard M Searfoss, Francisca N de Luna Vitorino, Joanna K Lempiäinen, Joanna Gongora, Zongtao Lin, Chenfeng Zhao and 2 more

Abstract read
In one paragraph

Article in Molecular & cellular proteomics : MCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Emily ZahnDepartment of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St Louis, Missouri, United States.
Yixuan XieDepartment of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St Louis, Missouri, United States; State Key Laboratory of Genetic Engineering, Greater Bay Area Institute of Precision Medicine (Guangzhou), School of Life Sciences and Institutes of Biomedical Sciences, Fudan University, Shanghai, China.
Xingyu LiuDepartment of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St Louis, Missouri, United States.
Rashmi KarkiDepartment of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St Louis, Missouri, United States.
Richard M SearfossDepartment of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St Louis, Missouri, United States.
Francisca N de Luna VitorinoDepartment of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St Louis, Missouri, United States.
Joanna K LempiäinenDepartment of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St Louis, Missouri, United States.
Joanna GongoraDepartment of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St Louis, Missouri, United States.
Zongtao LinDepartment of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St Louis, Missouri, United States.
Chenfeng ZhaoDepartment of Computer Science and Engineering, Washington University in St Louis, St Louis, Missouri, United States.
Zuo-Fei YuanCenter for Proteomics and Metabolomics, St Jude Children's Research Hospital, Memphis, Tennessee, United States.
Benjamin A GarciaDepartment of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St Louis, Missouri, United States. Electronic address: bagarcia@wustl.edu.

Funding

Research Education ComponentP30AG066444 · NIA · WASHINGTON UNIVERSITY · PI Susan Lynn Stark · 2020 to 2026
$28.7M
Shared Resources Core 2: Quantitative Proteomics CoreP01CA196539 · NCI · ROCKEFELLER UNIVERSITY · PI YOUNG, MICHAEL WARREN · 2015 to 2024
$17.6M
Viral modulation of epitranscriptomic mechanismsR01AI118891 · NIAID · WASHINGTON UNIVERSITY · PI GARCIA, BENJAMIN A, WEITZMAN, MATTHEW D. · 2015 to 2025
$5.4M
Chromatin Biology of the African TrypanosomeR01AI165840 · NIAID · THOMAS JEFFERSON UNIVERSITY · PI DEBLER, ERIK · 2022 to 2025
$2.8M
Quantitative mass spectrometry for comprehending epigenetic mechanisms in a new underlying neurological developmental disorderR01HD106051 · NICHD · WASHINGTON UNIVERSITY · PI Benjamin A Garcia · 2022 to 2026
$2.6M
Development and Application of Chemical Biology Approaches for Understanding Protein ArginylationR01HL177113 · NHLBI · WASHINGTON UNIVERSITY · PI Benjamin A Garcia, Zongtao Lin · 2025 to 2026
$1.2M
NCI NIH HHS P01 CA196539NHLBI NIH HHS R01 HL177113NIAID NIH HHS R01 AI118891NIAID NIH HHS R01 AI165840NIA NIH HHS P30 AG066444NICHD NIH HHS R01 HD106051
6 · The paper itself

Abstract

Histone post-translational modifications (PTMs) regulate gene expression patterns through epigenetic mechanisms. The five histone proteins (H1, H2A, H2B, H3, and H4) are extensively modified, with over 75 distinct modification types spanning more than 200 sites. Despite strong advances in mass spectrometry (MS)-based approaches, identification and quantification of modified histone peptides remains challenging because of factors, such as isobaric peptides, pseudo-isobaric PTMs, and low stoichiometry of certain marks. Here, we describe the development of a new high-throughput method to identify and quantify over 150 modified histone peptides by LC-MS. Fast gradient microflow liquid chromatography and variable window sequential windows acquisition of all theoretical spectra data-independent acquisition on a new quadrupole time-of-flight platform is compared to a previous method using nanoflow LC-MS on an Orbitrap hybrid. Histones extracted from cells treated with either a histone deacetylase inhibitor or transforming growth factor-beta 1 were analyzed by data-independent acquisition on two mass spectrometers: an Orbitrap Exploris 240 with a 55-min nanoflow LC gradient and the SCIEX ZenoTOF 7600 with a 10-min microflow gradient. To demonstrate the reproducibility and speed advantage of the method, 100 consecutive injections of one sample were performed in less than 2 days on the quadrupole time-of-flight platform. The result is the comprehensive characterization of histone PTMs achieved in less than 20 min of total run time using only 200 ng of sample. Results for drug-treated histone samples are comparable to those produced by the previous method and can be achieved using less than one-third of the instrument time.

Indexed as

High-Throughput Screening AssaysHistonesMass SpectrometryProtein Processing, Post-TranslationalChromatography, LiquidHistone Deacetylase InhibitorsHumansPeptidesProteomicsHistone Deacetylase InhibitorsHistonesPeptidesDIAepigeneticshistonemass spectrometrypost-translational modification

Identifiers

PMID39708910
PMCPMC11787651

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.